trending Market Intelligence /marketintelligence/en/news-insights/trending/ayu1x937aoo4rppj37chfg2 content esgSubNav
In This List

ATyr Pharma director forgoes re-election

Blog

Insight Weekly: US bank stress tests; cracks in housing market; summer energy supply risks

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches


ATyr Pharma director forgoes re-election

Srinivas Akkaraju decided not to stand for re-election as a director after completing his term at aTyr Pharma Inc.'s 2018 annual meeting of stockholders on May 15.

Akkaraju's decision not to stand for re-election was not a result of a disagreement with management regarding the company's operations, policies, practices or otherwise, according to ATyr Pharma.

San Diego, Calif.-based aTyr Pharma is a clinical stage biotherapeutics company, which engages in the discovery and development of Physiocrine-based therapeutics for patients suffering from severe and rare diseases.